Press release
Recurrent Glioblastoma Multiforme Gbm Treatment Market to Reflect Steady Growth Rate by 2022
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above.Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.
Request Sample Report @https://www.persistencemarketresearch.com/samples/10112
Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then treating with chemotherapy and radiation. While this treatment plan is the currently accepted standard of care, it does not effectively prevent tumor recurrence, which ultimately causes death in GBM patients. This factor is expected to be the prime restraint for the growth of recurrent glioblastoma multiforme market.
Recurrent Glioblastoma Multiforme (GBM) market is segmented on the basis of treatment, end user and geography.
Based on treatment, GBM market can be segmented as follows:
Oral Medications
Temozolomide
Radiosensitizers
Nitrosoureas Drugs
Radiation therapy
Chemotherapy
Based on end user, GBM market can be segmented as follows:
Hospitals
Clinics
Ambulatory surgical centers
Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for patients with unfavorable low-grade glioma to improve progression free survival. The most frequently used chemotherapy regimens are a combination of procarbazine, lomustine and vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM treatment market to a great extent.
Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominates the global GBM market owing to rising awareness, population aging, changing lifestyle and increasing healthcare awareness accentuates the growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an emerging market due to increasing demand for better healthcare facilities.
Request to View TOC @https://www.persistencemarketresearch.com/toc/10112
Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: himanshu.t@persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recurrent Glioblastoma Multiforme Gbm Treatment Market to Reflect Steady Growth Rate by 2022 here
News-ID: 1096646 • Views: …
More Releases from Persistence Market Research

Waterborne Polyurethane Dispersions Market Expected to Surpass US$ 2.83 Bn by 20 …
Introduction
The Waterborne Polyurethane Dispersions (WPUDs) Market is experiencing substantial growth due to the increasing preference for environmentally friendly materials in coatings, adhesives, and textile applications. With industries shifting towards sustainable alternatives, WPUDs are gaining traction as low-VOC, high-performance solutions across various sectors. This report explores the key drivers, market trends, challenges, and growth opportunities shaping the future of the waterborne polyurethane dispersions market.
WPUDs offer benefits such as excellent film formation,…

Silica Analyzer Market to Reach US$ 194.2 Mn by 2031 - Persistence Market Resear …
Introduction:
The silica analyzer market is a crucial segment within the industrial instrumentation industry, primarily used for monitoring silica levels in water and steam cycles to prevent scaling and corrosion in critical systems. With increasing demand for efficient and precise water quality monitoring solutions across industries such as power generation, semiconductors, and pharmaceuticals, the market is poised for steady growth.
This report provides a comprehensive analysis of the silica analyzer market, exploring…

Mobile Handset Protection Market Set for US$ 38.1 Billion by 2031 - Persistence …
Introduction
The mobile handset protection market is rapidly gaining traction as the global reliance on smartphones continues to grow. With the increasing cost of mobile devices and the demand for uninterrupted connectivity, consumers are actively seeking protection plans, extended warranties, and insurance options to safeguard their investments. This report explores the key drivers, challenges, technological advancements, and future opportunities within the mobile handset protection market.
Mobile handset protection services provide coverage for…

Physician Scheduling Systems Market Projected to Surge to US$ 2.03 Bn by 2033 - …
Introduction:
The physician scheduling systems market is experiencing rapid growth as healthcare organizations increasingly adopt digital solutions to optimize workforce management. These systems streamline physician scheduling, improve operational efficiency, and enhance patient care by reducing administrative burdens on medical professionals.
As healthcare institutions face rising patient loads, staffing shortages, and regulatory challenges, the need for automated scheduling solutions has become more critical than ever. Physician scheduling systems help hospitals, clinics, and private…
More Releases for GBM
Glioblastoma Multiforme Treatment (GBM) Market: Trends, Opportunities & Regional …
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and…
Glioblastoma Multiforme (GBM) Market : Global Market Revenue and Share by Manufa …
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
Summary:
ReportsWeb.com published “Glioblastoma Multiforme (GBM)” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Original Content:
Publisher's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials…
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging…